Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …

DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research
into the mechanisms underlying response to ICB has predominantly focused on T cells; …

Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …

The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

The clinical relevance of comprehensive molecular analysis in rare cancers is not
established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients …

Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …

Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting
the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many …

Effective predictive biomarkers are needed to enable personalized medicine and increase
treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and …